Oliver K Jawitz1, Amanda S Stebbins2, Vignesh Raman3, Brooke Alhanti2, Sean van Diepen4, Matthias Heringlake5, Stephen Fremes6, Richard Whitlock7, Steven R Meyer8, Rajendra H Mehta2, Mark Stafford-Smith9, Shaun G Goodman10, John H Alexander2, Renato D Lopes2. 1. Department of Surgery, Duke University Medical Center, Durham, NC; Duke Clinical Research Institute, Duke University Medical Center, Durham, NC. Electronic address: oliver.jawitz@duke.edu. 2. Duke Clinical Research Institute, Duke University Medical Center, Durham, NC. 3. Department of Surgery, Duke University Medical Center, Durham, NC. 4. Department of Critical Care and Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada; Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada. 5. Department of Anesthesia, University of Lübeck, Lübeck, Germany. 6. Department of Surgery, University of Toronto, Toronto, Ontario, Canada. 7. Department of Surgery, McMaster University, Hamilton, Ontario, Canada. 8. Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada. 9. Department of Anesthesiology, Duke University Medical Center, Durham, NC. 10. Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; St. Michael's Hospital, University of Toronto, Ontario, Canada.
Abstract
OBJECTIVES: We aimed to evaluate the association between levosimendan treatment and acute kidney injury (AKI) as well as assess the clinical sequelae of AKI in cardiac surgery patients with depressed left ventricular function (ejection fraction <35%). METHODS: Patients in the LEVO-CTS trial undergoing on-pump coronary artery bypass grafting (CABG), valve, or CABG/valve surgery were stratified by occurrence and severity of postoperative AKI using the AKIN classification. The association between levosimendan infusion and AKI was modeled using multivariable regression. RESULTS: Among 854 LEVO-CTS patients, 231 (27.0%) experienced postoperative AKI, including 182 (21.3%) with stage 1, 35 (4.1%) with stage 2, and 14 (1.6%) with stage 3 AKI. The rate of AKI was similar between patients receiving levosimendan or placebo. The odds of 30-day mortality significantly increased by AKI stage compared to those without AKI (stage 1: adjusted odds ratio [aOR] 2.0, 95% confidence interval [CI] 0.8-4.9; stage 2: aOR 9.1, 95% CI 3.2-25.7; stage 3: aOR 12.4, 95% CI 3.0-50.4). No association was observed between levosimendan, AKI stage, and odds of 30-day mortality (interaction P = .69). Factors independently associated with AKI included increasing age, body mass index, diabetes, and increasing baseline systolic blood pressure. Increasing baseline eGFR and aldosterone antagonist use were associated with a lower risk of AKI. CONCLUSIONS: Postoperative AKI is common among high-risk patients undergoing cardiac surgery and associated with significantly increased risk of 30-day death or dialysis. Levosimendan was not associated with the risk of AKI.
OBJECTIVES: We aimed to evaluate the association between levosimendan treatment and acute kidney injury (AKI) as well as assess the clinical sequelae of AKI in cardiac surgery patients with depressed left ventricular function (ejection fraction <35%). METHODS: Patients in the LEVO-CTS trial undergoing on-pump coronary artery bypass grafting (CABG), valve, or CABG/valve surgery were stratified by occurrence and severity of postoperative AKI using the AKIN classification. The association between levosimendan infusion and AKI was modeled using multivariable regression. RESULTS: Among 854 LEVO-CTS patients, 231 (27.0%) experienced postoperative AKI, including 182 (21.3%) with stage 1, 35 (4.1%) with stage 2, and 14 (1.6%) with stage 3 AKI. The rate of AKI was similar between patients receiving levosimendan or placebo. The odds of 30-day mortality significantly increased by AKI stage compared to those without AKI (stage 1: adjusted odds ratio [aOR] 2.0, 95% confidence interval [CI] 0.8-4.9; stage 2: aOR 9.1, 95% CI 3.2-25.7; stage 3: aOR 12.4, 95% CI 3.0-50.4). No association was observed between levosimendan, AKI stage, and odds of 30-day mortality (interaction P = .69). Factors independently associated with AKI included increasing age, body mass index, diabetes, and increasing baseline systolic blood pressure. Increasing baseline eGFR and aldosterone antagonist use were associated with a lower risk of AKI. CONCLUSIONS: Postoperative AKI is common among high-risk patients undergoing cardiac surgery and associated with significantly increased risk of 30-day death or dialysis. Levosimendan was not associated with the risk of AKI.
Authors: Rajendra H Mehta; Jeffrey D Leimberger; Sean van Diepen; James Meza; Alice Wang; Rachael Jankowich; Robert W Harrison; Douglas Hay; Stephen Fremes; Andra Duncan; Edward G Soltesz; John Luber; Soon Park; Michael Argenziano; Edward Murphy; Randy Marcel; Dimitri Kalavrouziotis; Dave Nagpal; John Bozinovski; Wolfgang Toller; Matthias Heringlake; Shaun G Goodman; Jerrold H Levy; Robert A Harrington; Kevin J Anstrom; John H Alexander Journal: N Engl J Med Date: 2017-03-19 Impact factor: 91.245
Authors: Juan M Mejía-Vilet; Victoria Ramírez; Cristino Cruz; Norma Uribe; Gerardo Gamba; Norma A Bobadilla Journal: Am J Physiol Renal Physiol Date: 2007-03-20
Authors: M Heringlake; M Knappe; O Vargas Hein; H Lufft; D Kindgen-Milles; B W Böttiger; M R Weigand; S Klaus; U Schirmer Journal: Minerva Anestesiol Date: 2006 Jul-Aug Impact factor: 3.051
Authors: María Ángeles Tena; Stefano Urso; Jesús María González; Luis Santana; Rafael Sadaba; Paula Juarez; Leonor González; Francisco Portela Journal: Interact Cardiovasc Thorac Surg Date: 2018-11-01
Authors: Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin Journal: Crit Care Date: 2007 Impact factor: 9.097